On January 25, 2024 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, reported that it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer (Press release, Panbela Therapeutics, JAN 25, 2024, View Source;utm_medium=rss&utm_campaign=panbela-exceeds-50-enrollment-for-aspire-trial-in-pancreatic-cancer [SID1234639478]). ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re thrilled to have surpassed 50% enrollment for the ASPIRE trial and to be moving faster than originally projected," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "As we have reached the near full complement of sites open and enrolling, we have seen a steady cadence of enrollment, expecting full enrollment to be completed by Q1 2025. We are looking forward to the interim data analysis based on overall survival in mid-2024."

In the global ASPIRE trial, there are approximately 90 sites up and running throughout the United States, Europe, Australia, and South Korea. Panbela is committed to delivering a more effective treatment for pancreatic cancer, a deadly disease with few treatment options.